4-tert-butyl-N-(6-bromoimidazo[1,2-a]pyridin-2-yl)benzamide | 1005775-52-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 4-tert-butyl-N-(6-bromoimidazo[1,2-a]pyridin-2-yl)benzamide
• 英文别名: N-(6-bromoimidazo[1,2-a]pyridin-2-yl)-4-tert-butylbenzamide
• CAS: 1005775-52-9
• 化学式: C₁₈H₁₈BrN₃O
• 分子量: 372.264
• InChiKey: JQUBHAZSXQUISS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-tert-butyl-N-(6-bromoimidazo[1,2-a]pyridin-2-yl)benzamide 、 3-吡啶硼酸 在 四(三苯基膦)钯 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 3.0h， 以38%的产率得到4-叔丁基-N-[6-(吡啶-3-基)咪唑并[1,2-a]吡啶-2-基]苯甲酰胺
  参考文献：
  名称：

  EP2058309

  摘要：

  公开号：
• 作为产物：
  描述：

  2-氨基-6-溴咪唑并[1,2-A]吡啶 、 对叔丁基苯甲酰氯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 4-tert-butyl-N-(6-bromoimidazo[1,2-a]pyridin-2-yl)benzamide
  参考文献：
  名称：

  Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors

  摘要：

  Imidazo[1,2-a]pyridine derivatives were designed, synthesized, and evaluated as inhibitors of the apoptosis signal-regulating kinase 1 (ASK1). These were based on a benzothiazole derivative that was discovered from high-throughput screening of our compound library. As a result, we identified potent, selective, and orally bioavailable ASK1 inhibitors for wide range of therapeutic targets. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.084

文献信息

• SULFONAMIDE-BASED ORGANOCATALYSTS AND METHOD FOR THEIR USE
  申请人：Carter Rich Garrett

  公开号：US20100184986A1

  公开（公告）日：2010-07-22

  Organocatalysts, particularly proline sulfonamide organocatalysts, having a first general formula as follows are disclosed. Embodiments of a method for using these organocatalysts also are disclosed. The method comprises providing a disclosed organocatalyst, and performing a reaction, often an enantioselective or diastereoselective reaction, using the organocatalyst. Solely by way of example, disclosed catalysts can be used to perform aldol reactions, conjugate additions, Michael additions, Robinson annulations, Mannich reactions, α-aminooxylations, α-hydroxyaminations, α-aminations and alkylation reactions. Certain of such reactions are intramolecular cyclizations used to form cyclic compounds, such as 5- or 6-membered rings, having one or more chiral centers. Disclosed organocatalysts generally are much more soluble in typical solvents used for organic synthesis than are known compounds. Moreover, the reaction yield is generally quite good with disclosed compounds, as is their enantioselective and diastereoselective effectiveness.

  披露了具有如下一般公式之一的有机催化剂，尤其是脯氨酸磺酰胺有机催化剂。还披露了使用这些有机催化剂的方法的实施例。该方法包括提供一种披露的有机催化剂，并使用该有机催化剂进行反应，通常是立体选择性的反应或对映选择性反应。仅作为示例，披露的催化剂可用于进行aldol反应、共轭加成、Michael加成、Robinson环化反应、Mannich反应、α-氨基氧化、α-羟基胺化、α-胺化和烷基化反应。其中一些反应是分子内环化反应，用于形成具有一个或多个手性中心的环状化合物，例如5或6元环。披露的有机催化剂通常比已知的化合物更容易溶于用于有机合成的典型溶剂中。此外，使用披露化合物的反应收率通常相当好，它们的对映选择性和非对映选择性效果也很好。
• FUSED HETEROCYCLIC COMPOUND
  申请人：Uchikawa Osamu

  公开号：US20100029619A1

  公开（公告）日：2010-02-04

  The present invention provides a compound represented by the formula (I): wherein ring A is a ring which is optionally further substituted; R 1 is a hydrogen atom or a substituent; R 2 is a hydrogen atom or a substituent; R 3 is a hydrogen atom or a substituent; R 4 is a hydrogen atom or a substituent; R 5 is a hydrogen atom or a substituent; R 6 is a hydrogen atom or a substituent; X is ═N— or ═C(Z)- (Z is a hydrogen atom or a substituent); when X is ═C(Z)-, Z and R 6 are optionally bonded to each other to form, together with the carbon atom bonded thereto, an optionally substituted ring, provided that when X is ═CH—, then R 6 is not optionally substituted 2-piperidinyl, excluding N-imidazo[1,2-a]pyridin-2-yl-4-methyl-benzamide, N-imidazo[1,2-a]pyridin-2-yl-benzamide and N-(7-methylimidazo[1,2-a]pyridin-2-yl)-benzamide, or a salt thereof, and a pharmaceutical agent containing same. The compound of the present invention has an ASK1 inhibitory action, and is useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, inflammatory diseases and the like, and the like.

  本发明提供了一种化合物，其化学式表示为（I）：其中，环A是一个环，可以进一步取代；R1是氢原子或取代基；R2是氢原子或取代基；R3是氢原子或取代基；R4是氢原子或取代基；R5是氢原子或取代基；R6是氢原子或取代基；X是═N-或═C(Z)-（其中Z是氢原子或取代基）；当X是═C(Z)-时，Z和R6可以选择性地结合在一起，形成一个可选取代的环，与其相连的碳原子一起；但是当X是═CH-时，R6不是可选取代的2-哌啶基，不包括N-咪唑[1,2-a]吡啶-2-基-4-甲基苯甲酰胺、N-咪唑[1,2-a]吡啶-2-基苯甲酰胺和N-(7-甲基咪唑[1,2-a]吡啶-2-基)-苯甲酰胺，或其盐，并且含有该化合物的药物。本发明的化合物具有ASK1抑制作用，可用作药物，例如预防或治疗糖尿病、炎症性疾病等药物。
• EP2058309
  申请人：——

  公开号：——

  公开（公告）日：——
• US8399684B2
  申请人：——

  公开号：US8399684B2

  公开（公告）日：2013-03-19
• Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors
  作者：Yoshito Terao、Hideo Suzuki、Masato Yoshikawa、Hiroaki Yashiro、Shiro Takekawa、Yasushi Fujitani、Kengo Okada、Yoshihisa Inoue、Yoshio Yamamoto、Hideyuki Nakagawa、Shuhei Yao、Tomohiro Kawamoto、Osamu Uchikawa

  DOI：10.1016/j.bmcl.2012.10.084

  日期：2012.12

  Imidazo[1,2-a]pyridine derivatives were designed, synthesized, and evaluated as inhibitors of the apoptosis signal-regulating kinase 1 (ASK1). These were based on a benzothiazole derivative that was discovered from high-throughput screening of our compound library. As a result, we identified potent, selective, and orally bioavailable ASK1 inhibitors for wide range of therapeutic targets. (C) 2012 Elsevier Ltd. All rights reserved.